Rafabegron
Code | Size | Price |
---|
TAR-T34256-1mg | 1mg | £303.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T34256-5mg | 5mg | £643.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T34256-10mg | 10mg | £863.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T34256-25mg | 25mg | £1,259.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T34256-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T34256-100mg | 100mg | £2,263.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Rafabegron (AJ-9677; TAK 677; AD 9677) is a potent and selective β3-adrenergic receptor agonist.
CAS:
244081-42-3
Formula:
C21H23ClN2O4
Molecular Weight:
402.88
Pathway:
GPCR/G Protein|Neuroscience
Purity:
0.98
SMILES:
C[C@H](Cc1c[nH]c2c(OCC(O)=O)cccc12)NC[C@H](O)c1cccc(Cl)c1
Target:
Adrenergic Receptor
References
Thiagamoorthy G, Giarenis I, Cardozo L. Early investigational ?3 adreno-receptor agonists for the management of the overactive bladder syndrome. Expert Opin Investig Drugs. 2015;24(10):1299-306. doi: 10.1517/13543784.2015.1076390. Epub 2015 Aug 14. PubMed PMID: 26292923.
Fujita M, Ueda T, Iwata M. Stabilization by meglumine of an amine compound degraded by formaldehyde in tablets. Int J Pharm. 2010 Feb 15;386(1-2):195-200. doi: 10.1016/j.ijpharm.2009.11.017. Epub 2009 Dec 2. PubMed PMID: 19931605.
Kullmann FA, Limberg BJ, Artim DE, Shah M, Downs TR, Contract D, Wos J, Rosenbaum JS, de Groat WC. Effects of beta3-adrenergic receptor activation on rat urinary bladder hyperactivity induced by ovariectomy. J Pharmacol Exp Ther. 2009 Sep;330(3):704-17. doi: 10.1124/jpet.109.155010. Epub 2009 Jun 10. PubMed PMID: 19515967; PubMed Central PMCID: PMC2729793.
Kullmann FA, Downs TR, Artim DE, Limberg BJ, Shah M, Contract D, de Groat WC, Rosenbaum JS. Urothelial beta-3 adrenergic receptors in the rat bladder. Neurourol Urodyn. 2011 Jan;30(1):144-50. doi: 10.1002/nau.20965. PubMed PMID: 21046653; PubMed Central PMCID: PMC3395322.